BioSpace News Archive

Revive Therapeutics Ltd. is pleased to announce that it has completed the formulation development work of the Company’s next-generation lyophilized formulation of Bucillamine (“New Bucillamine”) conducted at the University of Waterloo.

EyePoint Pharmaceuticals, Inc. today announced that the first patient has been dosed in the Phase 2 VERONA clinical trial of EYP-1901 for diabetic macular edema (DME).

Walden Biosciences, Inc. today announced that it has broadened its research collaboration with the University of Michigan at Ann Arbor (U-M).

Willow Biosciences Inc. (“Willow”) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, is pleased to provide a summary of its successes in 2023 and outline its plans for growth across all aspects of its business in 2024.

Medicinal chemists at Usona Institute have designed a series of new compounds inspired by norpsilocin, a tryptamine natural product found in psychedelic mushrooms.

According to preclinical research published online in Cell researchers with City of Hope®, one of the largest cancer treatment and research organizations in the United States, have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer.

BeyondSpring Inc. announced that on January 4, 2024, it received a Foreign Delinquency Compliance Plan Alert Letter from The Nasdaq Stock Market LLC.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”) today announced it has entered into an exclusive multi-year distribution agreement with Stedical Scientific, Inc. to commercialize PermeaDerm® Biosynthetic Wound Matrix in the United States.

Integer Holdings Corporation announced fourth quarter 2023 preliminary unaudited sales are expected to be in the range of $411 million to $413 million, an increase of 10% to 11% compared to fourth quarter 2022.

Gritstone bio, Inc. announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 18,500 shares of its common stock with an exercise price of $2.10, which is equal to the closing price of Gritstone’s common stock on January 4, 2024, the date of the grant.